Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.

Camptothecins are DNA topoisomerase I-directed anti-tumour drugs with a novel mechanism of action. Topotecan (TPT), a hydrophilic derivative of camptothecin, is currently undergoing phase II clinical trials in small-cell lung cancer (SCLC). Human SCLC OC-NYH cells were made more than 6-fold resistant to topotecan by stepwise drug exposure and resistance was stable for 70 passages without drug. NYH/TPT cells had half the topoisomerase I level and activity of wild-type cells. However, no difference in camptothecin or topotecan inhibition of topoisomerase I-mediated DNA relaxation was found, indicating that the enzyme itself was unchanged in the resistant cell. In NYH/TPT cells, topoisomerase II alpha and beta levels were increased approximately 2-fold. Accordingly, the topoisomerase II-directed drug etoposide (VP-16) induced an increased number of DNA single-strand breaks in NYH/TPT cells. However, sensitivity to different topoisomerase II-targeting agents in NYH/TPT cells varied from increased to decreased, indicating a role for as yet unidentified factors acting on the pathway to cell death after topoisomerase II-induced DNA damage has occurred. Of 20 anti-cancer agents tested, only hydroxyurea showed marked collateral hypersensitivity in NYH/TPT cells.

• Publication year

  1995

• Venue

  British Journal of Cancer

• Publication date

  1995-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/bjc.1995.345PMID 7640225PMCID 2034011
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.

  1994cited by this paper
• Elevated DNA Polymerase α, DNA Polymerase β, and DNA Topoisomerase II in a Melphalan-resistant Rhabdomyosarcoma Xenograft That Is Cross-Resistant to Nitrosoureas and Topotecan

  1994cited by this paper
• Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.

  1994cited by this paper
• The current status of camptothecin analogues as antitumor agents.

  1993cited by this paper
• Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation.

  1993cited by this paper
• Characterization of camptothecin-resistant Chinese hamster lung cells.

  1992cited by this paper
• Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.

  1992cited by this paper
• Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line.

  1992cited by this paper
• Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.

  1992influential reference
• Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture.

  1992cited by this paper
• Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells.

  1991cited by this paper
• Principles and practice of DNA filter elution.

  1991cited by this paper
• Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.

  1990cited by this paper
• Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines.

  1990cited by this paper
• Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.

  1990cited by this paper
• Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance.

  1990cited by this paper
• Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines.

  1990cited by this paper
• Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines.

  1989cited by this paper
• DNA topoisomerase poisons as antitumor drugs.

  1989cited by this paper
• Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.

  1989cited by this paper
• H2O2 as a DNA fragmenting agent in the alkaline elution interstrand crosslinking and DNA-protein crosslinking assays.

  1988cited by this paper
• Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.

  1988cited by this paper
• ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells.

  1988cited by this paper
• Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins.

  1988cited by this paper
• Inter-experiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell lines.

  1987cited by this paper
• Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.

  1987cited by this paper
• Characterization of three new variant type cell lines derived from small cell carcinoma of the lung.

  1985cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line

  2020cites this paper
• Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations

  2016cites this paper
• Correlation between topoisomerase I and tyrosyl-DNA phosphodiesterase 1 activities in non-small cell lung cancer tissue.

  2015cites this paper
• DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer

  2015cites this paper
• Decreased Camptothecin Sensitivity of the Stem-Cell-Like Fraction of Caco2 Cells Correlates with an Altered Phosphorylation Pattern of Topoisomerase I

  2014cites this paper
• Camptothecin resistance in cancer: insights into the molecular mechanisms of a DNA-damaging drug.

  2013cites this paper
• Topoisomerase IIβ Deficiency Enhances Camptothecin-induced Apoptosis*

  2013cites this paper
• Topoisomerase I Inhibitors – The Camptothecins

  2011cites this paper
• Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity

  2009cites this paper
• Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.

  2008cites this paper
• Phenotypic variations and chemosensitivity in small cell lung cancer

  2008cites this paper
• Mechanisms of cellular resistance to camptothecins.

  2006cites this paper
• Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines

  2006cites this paper
• Mechanisms of Resistance to Anticancer Agents

  2005cites this paper
• Clinical Experience With Topotecan

  2005cites this paper
• A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed‐dose oral etoposide in patients with solid tumors

  2004cites this paper
• Loss of Nonhomologous End Joining Confers Camptothecin Resistance in DT40 Cells

  2004cites this paper
• The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells

  2004cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  2002cites this paper
• A Phase I Clinical Trial of Sequentially Administered Doxorubicin and Topotecan in Refractory Solid Tumors 1

  2002cites this paper
• A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.

  2002cites this paper
• Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.

  2001cites this paper
• Characterization of cell lines resistant to topoisomerase targeting drugs and mechanistic studies of Quinoxaline solid tumor drugs - a new chemical class of topoisomerase II poisons /

  2001cites this paper
• Irinotecan in the treatment of colorectal cancer: clinical overview.

  2001cites this paper
• New Advances in Lung Cancer Chemotherapy: Topotecan and the Role of Topoisomerase I Inhibitors

  2001cites this paper
• A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer.

  2000cites this paper
• Preclinical Evaluation of Irinotecan

  2000cites this paper
• Deficient activation of CD95 (APO-1/ Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma

  2000cites this paper
• BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.

  2000cites this paper
• Synergistic Cytotoxicity, Apoptosis and Protein-linked DNA Breakage by Etoposide and Camptothecin in Human U87 Glioma Cells: Dependence on Tyrosine Phosphorylation

  1999cites this paper
• Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines

  1999cites this paper
• Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.

  1999cites this paper
• A PCR-aided transcript titration assay (PATTY) to measure topoisomerase I gene expression in human tumor specimens.

  1999cites this paper
• Topoisomerase I inhibitors: selectivity and cellular resistance.

  1999cites this paper
• Twenty-five years of chemotherapy in small cell lung cancer sends us back to the laboratory.

  1999cites this paper
• Topotecan

  1999cites this paper
• Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

  1998cites this paper
• DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.

  1998cites this paper
• Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death.

  1998cites this paper
• Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.

  1998cites this paper
• Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.

  1997cites this paper
• Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.

  1997cites this paper
• Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.

  1997cites this paper
• Review : Topoisomerase I inhibitors: 1. Topotecan

  1997cites this paper
• 2 Recent Advances in the Medicinal Chemistry and Pharmacology of Camptothecin

  1997cites this paper
• pH-dependent regulation of camptothecin-induced cytotoxicity and cleavable complex formation by the antimalarial agent chloroquine.

  1997cites this paper
• In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.

  1997cites this paper
• Targeted disruption of the mouse topoisomerase I gene by camptothecin selection

  1996cites this paper
• Cellular Resistance to Camptothecins

  1996cites this paper
• Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.

  1996cites this paper
• Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.

  1996cites this paper
• Factors Affecting Topotecan Sensitivity in Human Leukemia Samples a

  1996cites this paper